北美肝癌诊断市场 – 行业趋势和 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

北美肝癌诊断市场 – 行业趋势和 2030 年预测

  • Medical Devices
  • Published Report
  • Apr 2023
  • North America
  • 350 页面
  • 桌子數: 145
  • 图号: 58

North America Liver Cancer Diagnostics Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 4,031.47 Million
Diagram Market Size (Forecast Year)
USD 6,707.57 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>北美肝癌诊断市场,按测试类型(影像学测试、活检、基因组测试等)、癌症分期(0 期、I 期、II 期、III 期和 IV 期)、癌症类型(原发性肝癌和继发性肝癌)、产品(基于平台的产品、基于仪器的产品、试剂盒和试剂以及其他消耗品)、技术(荧光原位杂交、下一代测序、荧光免疫测定、比较基因组杂交、免疫组织化学等)、应用(筛查、诊断和预测、预后和研究)、性别(女性和男性)、最终用户(医院、诊断中心、癌症研究中心、学术机构、门诊手术中心等)、分销渠道(直接招标、零售销售等)划分 - 行业趋势和预测到 2030 年。

北美肝癌诊断市场

北美肝癌诊断市场分析与洞察  

由于市场参与者的增加和先进服务的可用性,北美肝癌诊断市场预计将在预测年内增长。与此同时,制造商正在从事研发活动,以在市场上推出新服务。对更高质量肝癌医疗服务的需求不断增长,以及对预防性健康检查的偏好不断增加,预计将推动市场的增长。

北美肝癌诊断市场北美肝癌诊断市场

北美肝癌诊断市场预计将在 2023 年至 2030 年的预测期内实现市场增长。Data Bridge Market Research 分析称,在 2023 年至 2030 年的预测期内,该市场将以 6.6% 的复合年增长率增长,预计到 2030 年将从 2022 年的 40.3147 亿美元达到 67.0757 亿美元。

北美肝癌诊断市场报告提供了市场份额、新发展和产品线分析的详细信息,国内和本地市场参与者的影响,分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景,请联系我们获取分析师简报。我们的团队将帮助您创建收入影响解决方案,以实现您的预​​期目标。各地区发展中国家零售单位的可扩展性和业务扩展以及与供应商合作安全分销机器和药品是推动预测期内市场需求的主要驱动力。

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021 (可定制为 2015-2020)

定量单位

收入(百万美元)

涵盖的领域

按检测类型(成像、活检、基因组检测等)、癌症分期(0 期、I 期、II 期、III 期和 IV 期)、癌症类型(原发性肝癌和继发性肝癌)、产品(基于平台的产品、基于仪器的产品、试剂盒和试剂及其他耗材)、技术(荧光原位杂交、下一代测序、荧光免疫测定、比较基因组杂交、免疫组织化学等)、应用(筛查、诊断和预测、预后和研究)、性别(女性和男性)、最终用户(医院、诊断中心、癌症研究中心、学术机构、门诊手术中心等)、分销渠道(直接招标、零售等)

覆盖国家

美国、加拿大、墨西哥

涵盖的市场参与者

Siemens Healthcare GmbH(德国)、Koninklijke Philips NV(荷兰)、安捷伦科技公司(美国)、Illumina 公司(美国)、Epigenomics AG(德国)、赛默飞世尔科技公司(美国)、QIAGEN(美国)、F. Hoffmann-La Roche Ltd(瑞士)、Diagnostic Biosystems Inc.(美国)、富士胶片株式会社(日本)、BD(美国)、MOLGEN(荷兰)、BIOCEPT, INC.(美国)、Sysmex Corporation(日本)、Elabscience Biotechnology Inc.(美国)、Hipro Biotechnology Co., Ltd.(中国)、Altogen Biosystems(美国)、ABK Biomedical Inc.(加拿大)、Diazyme Laboratories, Inc.(美国)和 AB Sciex Pte Ltd.(丹纳赫子公司)(美国)等

市场定义

肝癌诊断是指用于检测和诊断肝癌的各种方法和技术。这可能包括实验室检查、影像学检查和体格检查。

肝癌诊断市场包括来自各种公司的广泛产品和服务,包括诊断实验室、医疗器械制造商和制药公司。肝癌发病率的上升和对准确可靠的诊断测试的需求不断增长推动了该市场的发展。

北美肝癌诊断市场动态

驱动程序

  • 对非侵入性、准确、可靠的早期癌症检测诊断测试的需求尚未得到满足

诊断技术也正成为将基础研究的最新进展转化为患者更好的临床治疗效果的重要工具。当今一些最令人振奋的科学发展,包括基因组学、蛋白质组学和其他“组学”技术,正在加速开发新型、快速、灵敏、侵入性更小且更准确的分子诊断测试。这极大地影响了更早、更准确地识别和治疗不同癌症的能力。通过根据每位患者独特的分子特征定制药物,诊断技术可以帮助医生做出更明智的治疗决策。

因此,对于早期癌症检测的非侵入性、准确、可靠的诊断测试的未满足需求预计将推动市场的增长。

  • 提高肝癌的早期诊断率

机器学习可以彻底改变早期癌症诊断,即训练计算机从复杂数据中发现规律。工具包括对常见健康数据、医学成像、活检样本和血液测试的评估,以帮助早期诊断和风险分层。在许多肿瘤类型中,早期癌症诊断可以增加成功治疗的可能性。一个重要的策略是评估没有表现出症状的高危患者,并对表现出症状的患者做出快速而适当的反应。

因此,早期检测可以改善治疗方案、患者治疗结果和生存率,并有望推动北美肝癌诊断市场的增长。

克制

  • 肝癌诊断障碍和不良预后

癌症是发达国家和发展中国家的主要死亡原因。预计到 2030 年,癌症死亡率将上升至每年约 1310 万人。但是,如果在早期发现并得到充分治疗,某些类型的癌症治愈的可能性很高。癌症诊断的延迟可能发生在整个诊断途径中:患者、初级保健和二级保健。当患者未能识别可疑的癌症症状并采取行动时,可能会发生患者延误。公众对早期癌症症状的认识不足被认为是延误就诊的主要原因,特别是当症状性质不典型时。

这些因素往往导致诊断延迟,从而导致预后不良。因此,预计这些因素将抑制北美肝癌诊断市场的增长。

机会

  • 提高对肝癌的认识

肝癌意识是增加人们对这些疾病的了解并关注其病因、预防、诊断、治疗和生存研究的机会。目标是帮助受肝脏影响的人并促进健康的习惯。原发性肝癌是指在肝脏中发生的癌症。肝细胞癌是成人中最常见的原发性肝癌 (HCC)。这种特殊形式的肝癌是全球癌症相关死亡的第三大常见原因。在美国,每年约有 25,000 名男性和 11,000 名女性被诊断出患有肝癌,这种疾病夺走了 19,000 名男性和 9,000 名女性的生命。

因此,政府针对肝癌诊断的举措有望为市场的增长创造机会。

挑战

  • 肝癌诊断产品审批严格

严格的产品审批和市场商业化指导方针已成为全球癌症诊断产品制造商面临的一大障碍。每个国家都有自己的法规,并采用不同的监管机构。

由于监管严格,医疗器械生产和营销的参与者必须做出调整。这将影响全球所有利益相关者,预计整个预测期内市场都将面临挑战。因此,预计这将对北美肝癌诊断市场构成挑战,阻碍其增长。

近期发展

  • 2022 年 12 月,富士胶片控股美国公司宣布,该公司与 Inspirata, Inc. 达成资产购买协议,收购数字病理学业务,以扩大其强大的企业成像产品。这使得病理学图像和数据能够集成到医疗机构的电子健康记录系统中,从而简化肿瘤患者的护理服务

北美肝癌诊断市场范围

北美肝癌诊断市场分为九个显著部分,分别是测试类型、癌症类型、癌症阶段、产品、应用、技术、性别、最终用户和分销渠道。

按测试类型

  • 影像检查
  • 活检
  • 基因组测试
  • 其他的

根据癌症分期

  • 第 0 阶段
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

按癌症类型

  • 原发性肝癌
  • 继发性肝癌

按产品

  • 基于平台的产品
  • 基于仪器的产品
  • 试剂盒和试剂
  • 其他耗材

按技术分类

  • 荧光原位杂交
  • 下一代测序
  • 荧光免疫分析法
  • 比较基因组杂交
  • 免疫组织化学
  • 其他的

按应用

  • 筛查
  • 诊断和预测
  • 预测
  • 研究

按性别

  • 女性
  • 男性

按最终用户

  • 医院
  • 癌症研究中心
  • 学术机构
  • 诊断中心
  • 门诊手术中心
  • 其他的

按分销渠道

  • 直接招标
  • 零售销售
  • 其他的

肝癌诊断市场

北美肝癌诊断市场区域分析/见解

根据测试类型、癌症阶段、癌症类型、产品、应用、技术、性别、最终用户和分销渠道,北美肝癌诊断市场分为九个显著部分。

本市场报告涵盖的国家包括美国、加拿大和墨西哥。

美国占据主导地位,因为其拥有最大的消费市场和较高的 GDP。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在对国家数据进行预测分析时,还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少竞争而面临的挑战,以及销售渠道的影响。

竞争格局和北美肝癌诊断市场份额分析

北美肝癌诊断市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对北美肝癌诊断市场的关注有关。

北美肝癌诊断市场的一些主要参与者包括西门子医疗有限公司(德国)、荷兰皇家飞利浦公司(荷兰)、安捷伦科技公司(美国)、Illumina 公司(美国)、Epigenomics AG(德国)、赛默飞世尔科技公司(美国)、QIAGEN(美国)、罗氏公司(瑞士)、Diagnostic Biosystems 公司(美国)、富士胶片株式会社(日本)、BD(美国)、MOLGEN(荷兰)、BIOCEPT 公司(美国)、Sysmex 公司(日本)、Elabscience Biotechnology 公司(美国)、Hipro Biotechnology 有限公司(中国)、Altogen Biosystems 公司(美国)、ABK Biomedical 公司(加拿大)、Diazyme Laboratories 公司(美国)、AB Sciex 私人有限公司(丹纳赫子公司)(美国)等。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 TEST TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTLE ANALYSIS

4.2 PORTER ANALYSIS

4.3 EPIDEMIOLOGY

5 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS

6 INDUSTRY INSIGHTS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION

7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER

7.1.3 INCREASING CASES OF LIVER CANCER

7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS

7.2 RESTRAINTS

7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS

7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS

7.3 OPPORTUNITIES

7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER

7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS

7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE

7.4 CHALLENGES

7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS

7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE

8 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 IMAGING TEST

8.2.1 MAGNETIC RESONANCE IMAGING (MRI)

8.2.1.1 MR ANGIOGRAPHY (MRA)

8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY

8.2.2 COMPUTED TOMOGRAPHY

8.2.3 POSITRON EMISSION TOMOGRAPHY

8.2.4 ULTRASOUND

8.2.5 OTHERS

8.3 GENOMIC TEST

8.4 BIOPSY

8.4.1 FINE NEEDLE ASPIRATION BIOPSY

8.4.2 CORE NEEDLE BIOPSY

8.4.3 LAPAROSCOPY

8.5 OTHERS

9 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE

9.1 OVERVIEW

9.2 STAGE III

9.3 STAGE II

9.4 STAGE IV

9.5 STAGE I

9.6 STAGE 0

10 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

10.1 OVERVIEW

10.2 SECONDARY LIVER CANCER

10.2.1 HEMANGIOMA

10.2.2 HEPATIC ADENOMA

10.2.3 FOCAL NODULAR HYPERPLASIA

10.3 PRIMARY LIVER CANCER

10.3.1 HEPATOCELLULAR CARCINOMA (HCC)

10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER)

10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA

10.3.4 HEPATOBLASTOMA

11 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT

11.1 OVERVIEW

11.2 PLATFORM BASED PRODUCTS

11.2.1 NEXT GENERATION SEQUENCING

11.2.2 MICROARRAYS

11.2.3 PCR

11.2.4 OTHERS

11.3 INSTRUMENT BASED PRODUCTS

11.3.1 IMAGING

11.3.2 BIOPSY

11.4 KITS AND REAGENTS

11.4.1 ELISA TEST KITS

11.4.2 CASSETTE TEST KITS

11.4.3 OTHERS

11.5 OTHER CONSUMABLES

12 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION

12.1 OVERVIEW

12.2 SCREENING

12.2.1 PLATFORM BASED PRODUCTS

12.2.2 INSTRUMENT BASED PRODUCTS

12.2.3 KITS AND REAGENTS

12.2.4 OTHER CONSUMABLES

12.3 DIAGNOSTIC AND PREDICTIVE

12.3.1 PLATFORM BASED PRODUCTS

12.3.2 INSTRUMENT BASED PRODUCTS

12.3.3 KITS AND REAGENTS

12.3.4 OTHER CONSUMABLES

12.4 PROGNOSTIC

12.4.1 PLATFORM BASED PRODUCTS

12.4.2 INSTRUMENT BASED PRODUCTS

12.4.3 KITS AND REAGENTS

12.4.4 OTHER CONSUMABLES

12.5 RESEARCH

12.5.1 PLATFORM BASED PRODUCTS

12.5.2 INSTRUMENT BASED PRODUCTS

12.5.3 KITS AND REAGENTS

12.5.4 OTHER CONSUMABLES

13 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

13.1 OVERVIEW

13.2 FLUORESCENT IN SITU HYBRIDIZATION

13.3 NEXT GENERATION SEQUENCING

13.4 FLUORIMMUNOASSAY

13.5 COMPARATIVE GENOMIC HYBRIDIZATION

13.6 IMMUNOHISTOCHEMICAL

13.7 OTHERS

14 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER

14.1 OVERVIEW

14.2 MALE

14.3 FEMALE

15 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 DIAGNOSTIC CENTERS

15.4 CANCER RESEARCH CENTERS

15.5 AMBULATORY SURGICAL CENTERS

15.6 ACADEMIC INSTITUTES

15.7 OTHERS

16 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 RETAIL SALES

16.4 OTHERS

17 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY REGION

17.1 NORTH AMERICA

17.1.1 U.S.

17.1.2 CANADA

17.1.3 MEXICO

18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 F. HOFFMANN-LA ROCHE LTD.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENT

20.2 KONINLIJKE PHILIPS N.V.

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 THERMO FISHER SCIENTIFIC INC.

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENT

20.4 BD

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENTS

20.5 SIEMENS HEALTHCARE GMBH

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENT

20.6 AGILENT TECHNOLOGIES, INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 REVENUE ANALYSIS

20.6.3 PRODUCT PORTFOLIO

20.6.4 RECENT DEVELOPMENTS

20.7 ABK BIOMEDICAL INC.

20.7.1 COMPANY SNAPSHOT

20.7.2 PRODUCT PORTFOLIO

20.7.3 RECENT DEVELOPMENT

20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.)

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 ALTOGEN BIOSYSTEMS

20.9.1 COMPANY SNAPSHOT

20.9.2 PRODUCT PORTFOLIO

20.9.3 RECENT DEVELOPMENT

20.1 BIOCEPT, INC.

20.10.1 COMPANY SNAPSHOT

20.10.2 REVENUE ANALYSIS

20.10.3 PRODUCT PORTFOLIO

20.10.4 RECENT DEVELOPMENT

20.11 BODITECH MED INC.

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENTS

20.12 DIAGNOSTIC BIOSYSTEMS INC.

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 DIAZYME LABORATORIES, INC.

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.14 ELABSCIENCE BIOTECHNOLOGY INC.

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.15 EPIGENOMICS AG

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANALYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENT

20.16 FUJIFILM CORPORATION

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 FUJIREBIO

20.17.1 COMPANY SNAPSHOT

20.17.2 PRODUCT PORTFOLIO

20.17.3 RECENT DEVELOPMENTS

20.18 HIPRO BIOTECHNOLOGY CO., LTD.

20.18.1 COMPANY SNAPSHOT

20.18.2 PRODUCT PORTFOLIO

20.18.3 RECENT DEVELOPMENT

20.19 ILLUMINA, INC.

20.19.1 COMPANY SNAPSHOT

20.19.2 REVENUE ANALYSIS

20.19.3 PRODUCT PORTFOLIO

20.19.4 RECENT DEVELOPMENTS

20.2 MOLGEN

20.20.1 COMPANY SNAPSHOT

20.20.2 PRODUCT PORTFOLIO

20.20.3 RECENT DEVELOPMENT

20.21 QIAGEN

20.21.1 COMPANY SNAPSHOT

20.21.2 REVENUE ANALYSIS

20.21.3 PRODUCT PORTFOLIO

20.21.4 RECENT DEVELOPMENT

20.22 Q-LINE BIOTECH PVT LTD.

20.22.1 COMPANY SNAPSHOT

20.22.2 PRODUCT PORTFOLIO

20.22.3 RECENT DEVELOPMENT

20.23 SYSMEX CORPORATION

20.23.1 COMPANY SNAPSHOT

20.23.2 REVENUE ANALYSIS

20.23.3 PRODUCT PORTFOLIO

20.23.4 RECENT DEVELOPMENT

20.24 TEBUBIO

20.24.1 COMPANY SNAPSHOT

20.24.2 PRODUCT PORTFOLIO

20.24.3 RECENT DEVELOPMENT

20.25 TOSOH INDIA PVT. LTD.

20.25.1 COMPANY SNAPSHOT

20.25.2 PRODUCT PORTFOLIO

20.25.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

表格列表

TABLE 1 DIFFERENT TYPES OF CANCER NON-INVASIVE SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS

TABLE 2 LIVER CANCER RATES

TABLE 3 APPROVED DIAGNOSTICS OF LIVER CANCER

TABLE 4 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA IMAGING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA GENETIC TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA STAGE III IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA STAGE II IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA STAGE IV IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA STAGE I IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA STAGE 0 IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA OTHER CONSUMABLES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA FLUORESCENT IN SITU HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA NEXT GENERATION SEQUENCING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA FLUORIMMUNOASSAY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA COMPARATIVE GENOMIC HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA IMMUNOHISTOCHEMICAL IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 48 NORTH AMERICA MALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA FEMALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA HOSPITALS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 NORTH AMERICA DIAGNOSTIC CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 NORTH AMERICA CANCER RESEARCH CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 NORTH AMERICA ACADEMIC INSTITUTES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 58 NORTH AMERICA DIRECT TENDER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 NORTH AMERICA RETAIL SALES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 62 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 63 NORTH AMERICA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 64 NORTH AMERICA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 65 NORTH AMERICA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 68 NORTH AMERICA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 76 NORTH AMERICA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 78 NORTH AMERICA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 79 NORTH AMERICA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 81 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 83 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 84 U.S. IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 85 U.S. MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 86 U.S. BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 87 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 88 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 89 U.S. SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 90 U.S. PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 91 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 92 U.S. PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 93 U.S. INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 U.S. KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 95 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 96 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 97 U.S. SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 98 U.S. DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 99 U.S. PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 100 U.S. RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 101 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 102 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 103 U.S. LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 104 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 105 CANADA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 106 CANADA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 107 CANADA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 108 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 109 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 110 CANADA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 111 CANADA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 112 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 113 CANADA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 114 CANADA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 115 CANADA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 116 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 117 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 118 CANADA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 119 CANADA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 120 CANADA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 121 CANADA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 122 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 123 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 124 CANADA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 125 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 126 MEXICO IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 127 MEXICO MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)

TABLE 128 MEXICO BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 129 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)

TABLE 130 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 131 MEXICO SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 132 MEXICO PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 133 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 134 MEXICO PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 135 MEXICO INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 136 MEXICO KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 137 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 138 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 139 MEXICO SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 140 MEXICO DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 141 MEXICO PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 142 MEXICO RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 143 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 144 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 145 MEXICO LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

图片列表

FIGURE 1 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 GROWING AWARENESS OF LIVER CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030

FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET

FIGURE 14 THE NORTH AMERICA MORTALITY RATE DUE TO CANCER

FIGURE 15 INCREASING NORTH AMERICA CANCER RATE IN 2020

FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT

FIGURE 17 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022

FIGURE 18 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)

FIGURE 19 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)

FIGURE 20 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 21 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2022

FIGURE 22 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)

FIGURE 23 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)

FIGURE 24 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE

FIGURE 25 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022

FIGURE 26 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)

FIGURE 27 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)

FIGURE 28 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 29 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022

FIGURE 30 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 31 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 32 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 33 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022

FIGURE 34 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 35 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 36 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 37 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022

FIGURE 38 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 39 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 40 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 41 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2022

FIGURE 42 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)

FIGURE 43 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 44 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 45 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2022

FIGURE 46 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 47 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 48 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 49 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 50 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 51 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 52 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 53 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)

FIGURE 54 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)

FIGURE 55 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 56 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 57 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)

FIGURE 58 NORTH AMERICA LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The North America Liver Cancer Diagnostics Market is projected to grow at a CAGR of 6.6% during the forecast period by 2030.
The future market value of the North America Liver Cancer Diagnostics Market is expected to reach USD 6,707.57 Million by 2030.
The North America Liver Cancer Diagnostics Market is segmented on the basis of test type, cancer type, cancer stages, product, application, technology, gender, end-user, and distribution channels.
The countries covered in the North America Liver Cancer Diagnostics Market are U.S., Canada, Mexico.